Method for treating aberrant fibrotic tissue manifestations with topical calcium channel blocker preparations and improved composition for such treatment and improved method for the manufacture thereof

Abstract

The invention is of an improved to topical medicament and associated methodology for use thereof, through the use of which aberrant fibrotic tissue manifestations involving scarring or sub-dermal plaque formations or accumulations may be effectively, cost effectively, and painlessly treated. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions and transdermal penetration agents or carriers are included to facilitate topical delivery of the active ingredient(s) to the intended, sub-dermal treatment site.

I claim:  
     
         1 . A medicament for use in the treatment of aberrant fibrotic tissue manifestations comprising: 
 a carrier host agent for facilitating transdermal application of a calcium channel blocker agent to an affected bodily structure;    a calcium channel blocker agent suspended in said carrier host agent; and    an antioxidant agent suspended in said carrier host agent for preventing the oxidation of active ingredients of said medicament.    
     
     
         2 . The medicament of  claim 1  wherein said calcium channel blocker agent is verapamil.  
     
     
         3 . The medicament of  claim 1  wherein said medicament comprises: 
 verapamil;  
 a lecithin/isopropyl myristate solution;  
 butylated hydroxy toluene;  
 pluronic F127; and  
 water.  
 
     
     
         4 . The medicament of  claim 3  further comprising: 
 Edetate disodium.  
 
     
     
         5 . The medicament of  claim 3  further comprising: 
 Propylene glycol.  
 
     
     
         6 . The medicament of  claim 4  further comprising: 
 Propylene glycol.  
 
     
     
         7 . A method for treating aberrant fibrotic tissue manifestations comprising the steps of: 
 selecting a medicament comprising: 
 carrier host agent for facilitating transdermal application of a calcium channel blocker agent to a bodily structure having an aberrant fibrotic tissue manifestation;  
 a calcium channel blocker agent suspended in said carrier host agent; and  
 an antioxidant agent suspended in said carrier host agent to four preventing oxidation of constituents of said medicament;  
   periodically, topically applying a therapeutic dosage of said medicament to a bodily structure which exhibits symptoms of a connective or elastic tissue disease.    
     
     
         8 . The method of  claim 3  wherein said calcium channel blocker agent is verapamil.  
     
     
         9 . The method of  claim 7  wherein said calcium channel blocker agent is selected from the chemical groups consisting of diphenylalkylamine, benzothiazepines, or dihydropryridines.